Europe Blood Plasma And Plasma Derived Medicinal Products Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
USD
7.96 Billion
USD
13.75 Billion
2024
2032
 예측 기간 |
2025 –2032 |
 시장 규모(기준 연도) |
USD 7.96 Billion |
 시장 규모(예측 연도) |
USD 13.75 Billion |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
|
유럽 혈장 및 혈장 유래 의약품 시장 세분화, 제품별( 면역글로불린 , 응고 인자(출혈 장애용), 알부민 (혈장 부피 확장제), 프로테아제 억제제(유전적 결핍용), 단일클론 항체(혈장 세포에서 유래) 및 기타 혈장 유래 단백질), 응용 분야(면역학, 혈액학, 중환자 치료, 신경학, 폐의학, 혈액종양학 , 류마티스학 및 기타 응용 분야), 처리 기술(이온 교환 크로마토그래피, 친화성 크로마토그래피, 극저온 침전, 초 여과 및 미세 여과), 모드(현대 및 전통 혈장 분획), 최종 사용자(병원 및 진료소, 연구실, 학술 기관 및 기타), 유통 채널(직접 입찰, 제3자 유통업체 및 기타) - 산업 동향 및 예측 2032
혈장 및 혈장 유래 의약품 시장 규모
- 유럽 혈장 및 혈장 유래 의약품 시장은 2024년에 79억 6천만 달러 규모로 평가되었으며, 예측 기간 동안 7.11%의 CAGR 로 2032년까지 137억 5천만 달러 에 도달할 것으로 예상됩니다 .
- 시장 성장은 주로 희귀 및 만성 질환의 유병률 증가에 의해 촉진됩니다.
- 더욱이, 혈장 및 혈장 유래 의약품의 혈장 분획 기술 발전이 두드러지고 있습니다. 이러한 융합 요인들은 혈장 및 혈장 유래 의약품 솔루션의 도입을 가속화하여 업계 성장을 크게 촉진하고 있습니다.
혈장 및 혈장 유래 의약품 시장 분석
- 혈우병, 면역결핍 장애, 자가면역 질환과 같은 질환을 치료하는 데 있어 혈장 유래 치료법에 대한 수요 증가로 시장이 확대되고 있으며, 이는 수혈 의학에 대한 인식이 높아지고 발전함에 따라 뒷받침되고 있습니다.
- 혈액 수집, 분획 및 냉장 물류 분야의 기술 발전으로 제품 품질과 유통 기한이 향상되어 전 세계 병원, 외상 센터 및 진단 실험실에서 더 폭넓은 도입이 촉진되고 있습니다.
- 독일은 개선된 의료 인프라, 혈장 치료제 수요 증가, 정부 지원 확대, 만성 및 감염성 질환 유병률 증가로 인해 2025년 혈장 및 혈장 유래 의약품 시장 점유율 18.16%를 기록하며 시장을 장악할 것으로 예상됩니다.
- 독일은 의료 투자 증가, 만성 및 감염성 질환 유병률 증가, 진단 시설 개선, 혈액 안전에 대한 인식 제고, 혈장 치료 접근성 및 인프라 강화를 위한 정부 이니셔티브로 인해 혈장 및 혈장 유래 의약품 시장에서 가장 빠르게 성장하는 지역이 될 것으로 예상됩니다.
- 면역글로불린 부문은 표적 치료에 대한 수요 증가, 정제 기술 개선, 면역 관련 질환 유병률 증가로 인해 2025년에 42.20%의 점유율로 혈장 및 혈장 유래 의약품 시장을 지배할 것으로 예상됩니다.
보고서 범위 및 혈장 및 혈장 유래 의약품 시장 세분화
|
속성 |
혈장 및 혈장 유래 의약품 주요 시장 통찰력 |
|
다루는 세그먼트 |
|
|
포함 국가 |
|
|
주요 시장 참여자 |
|
|
시장 기회 |
|
|
부가가치 데이터 정보 세트 |
Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 적용 범위, 주요 기업 등 시장 시나리오에 대한 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함됩니다. |
혈장 및 혈장 유래 의약품 시장 동향
“희귀 및 만성 질환 유병률 증가”
- 혈장 및 혈장 유래 의약품 시장의 주요 원동력은 진단 기술의 발전과 의료 서비스 제공자 및 환자의 인식 제고로 인해 전 세계적으로 희귀 및 만성 질환의 유병률이 증가하고 있다는 것입니다.
- 예를 들어, 2025년 4월 미국 질병통제예방센터(CDC) 데이터에 따르면 미국 성인의 76.4%가 최소 한 가지 만성 질환을 앓고 있었고, 51.4%는 여러 질환을 앓고 있었습니다. 젊은 성인에서도 관찰되는 이러한 증가 추세는 특히 혈우병, 원발성 면역결핍증, 폰 빌레브란트병과 같은 질환에 대한 평생 치료에 대한 수요를 증가시켰습니다.
- 면역글로불린, 응고인자, 알부민과 같은 혈장 유래 치료제는 이러한 평생 질환을 관리하는 데 필수적입니다. 원발성 면역결핍증 환자는 면역 지원을 위해 IVIG에 의존하는 반면, 혈우병 환자는 출혈을 예방하기 위해 정기적인 응고인자 주입이 필요합니다.
- 전 세계 인구 고령화로 인해 이러한 추세가 더욱 가속화되고 있으며, 노인들은 간경변, 다발성 골수종, 염증성 질환과 같은 질환에 점점 더 많이 시달리고 있으며 이러한 질환들은 모두 혈장 유래 개입을 필요로 합니다.
- 2025년 3월, PMC에 발표된 연구는 희귀 질환, 특히 소아 환자의 전 세계적인 부담이 얼마나 큰지를 강조했습니다. 유전체 의학과 희귀의약품 개발의 발전에도 불구하고, 진단 지연과 제한된 치료 옵션은 여전히 남아 있어 다학제적이고 지속적인 치료의 필요성을 강조합니다.
- 안전하고 효과적이며 고품질의 혈장 유래 치료법에 대한 수요 증가는 혈장 및 혈장 유래 의약품 시장을 주도하는 핵심 요인입니다. 이러한 제품은 평생 질병을 관리하고 유럽의 충족되지 않은 의료 요구 사항을 해결하는 데 중요한 역할을 하기 때문입니다.
혈장 및 혈장 유래 의약품 시장 동향
운전사
“노인 인구 확대”
- 혈장 및 혈장 유래 의약품에 대한 수요 증가는 면역 체계 장애, 신경 질환, 간 합병증 및 면역글로불린, 알부민, 응고 인자를 포함한 혈장 기반 치료법이 필요한 혈액 관련 문제와 같은 만성 및 퇴행성 질환에 더 취약한 고령화된 세계 인구에 의해 크게 촉진됩니다.
- 예를 들어, 2025년 3월, PMC에 게재된 연구에서는 2010년부터 2024년까지 미국 국립 입원 환자 표본(NIS) 데이터를 분석하여 고령 인구의 급격한 증가로 인해 입원, 입원 기간 연장, 그리고 재입원율이 크게 증가한 것으로 나타났습니다. 만성 질환과 복합 질환으로 인한 이러한 추세는 의료 시스템의 부담 증가와 그에 따른 혈장 유래 치료제 수요 증가를 보여줍니다.
- 나이가 들면서 면역 체계가 약화되어 감염 및 자가면역 질환에 대한 취약성이 증가합니다. 면역글로불린 요법은 만성 염증성 탈수초성 다발신경병증(CIDP)과 같은 질환 치료에 자주 사용되는 반면, 알부민은 고령 환자의 수술 및 중환자 치료 시 체액 균형 조절에 필수적입니다.
- 고령 인구 비율이 높은 국가에서는 PDMP(혈장분리막) 소비가 지속적으로 증가하고 있습니다. 이러한 인구학적 추세는 국가 의료 시스템에 중단 없는 공급망과 충분한 혈장 수집을 보장해야 하는 엄청난 부담을 안겨줍니다.
- 세계보건기구(WHO) 추산에 따르면 2023년 11억 명이었던 전 세계 60세 이상 인구가 2050년에는 21억 명으로 증가할 것으로 예상됨에 따라 노인 의료의 중요성이 더욱 강조됩니다. 이러한 인구학적 변화는 장기적인 치료 지원의 필요성을 증폭시킬 뿐만 아니라, 유럽에서 노인 인구를 PDMP의 핵심적이고 지속적인 시장 부문으로 자리매김하게 합니다.
제지/도전
“ 고비용 및 복잡한 제조 공정 ”
- 혈장 및 혈장 유래 의약품 제조에 따르는 높은 비용과 복잡성은 시장 확장에 큰 걸림돌이 됩니다. 이 공정은 엄격한 혈장 채취 프로토콜, 광범위한 병원균 검사, 그리고 무균 및 GMP 준수 환경에서의 다단계 분획을 요구하기 때문에 생산에 막대한 자원과 시간이 소요될 수 있습니다.
- 예를 들어, Aykon Biosciences의 상세 분석에 따르면 혈장 유래 치료제와 같은 복잡한 생물학적 제제 제조는 값비싼 원자재, 숙련된 인력 요구, 그리고 점점 더 엄격해지는 규제 준수 요구로 인해 비용 압박이 증가하고 있습니다. 전문화되고 개인화된 치료법으로의 전환은 비용을 더욱 증가시켜 첨단 기술과 엄격한 품질 보증 시스템을 필요로 합니다.
- 또한, PDMP의 제조 주기는 최대 12개월까지 길어질 수 있으며, 공정 전반에 걸쳐 보관 및 운송을 위한 콜드체인 물류가 필요합니다. 이러한 요인들은 자본 및 운영 비용을 크게 증가시켜 확장성을 제한하고 소규모 업체와 개발도상국의 시장 참여를 저해합니다.
- 생산 비용 집약적인 특성 또한 최종 제품 가격 상승에 영향을 미쳐, 특히 의료 예산이 부족한 저소득 및 중소득 국가에서 접근성과 구매력을 저하시킵니다. 이러한 재정적 부담은 증가하는 글로벌 수요를 충족하는 데 어려움을 야기하여, 전 세계적으로 PDMP의 광범위한 도입을 저해합니다.
- 지속적인 기술 혁신을 통해 비용 효율성이 점진적으로 향상될 수 있지만, 현재의 높은 생산 및 가공 비용은 여전히 주요 제약 요소로 남아 있습니다. 제조 기술 개선, 공여 인프라 확대, 그리고 적극적인 공중 보건 기금 지원을 통해 이러한 과제를 해결하는 것은 더 넓은 시장 접근성과 공평한 치료 보장을 확보하는 데 필수적입니다.
혈장 및 혈장 유래 의약품 시장 범위
시장은 제품, 응용 분야, 처리 기술, 모드, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다.
- 제품별
제품별로 시장은 면역글로불린, 응고인자(출혈 질환 치료), 알부민(혈장량 증가제), 프로테아제 억제제(유전적 결핍 치료), 단일클론 항체(혈장 세포 유래) 및 기타 혈장 유래 단백질로 세분화됩니다. 2025년에는 면역글로불린 부문이 면역결핍 진단 증가, 자가면역 질환, 그리고 정맥 면역글로불린(IVIG) 사용 증가에 힘입어 42.20%의 시장 점유율을 기록하며 시장을 주도할 것으로 예상됩니다.
응고 인자(출혈성 질환 치료) 부문은 혈우병 환자 증가, 진단 접근성 향상, 정부 지원, 재조합 및 혈장 유래 치료법 사용 확대에 힘입어 2025년부터 2032년까지 7.27%의 가장 빠른 성장률을 보일 것으로 예상됩니다.
- 응용 프로그램별
응용 분야별로 시장은 면역학, 혈액학, 중환자 치료, 신경학, 폐의학, 혈액종양학, 류마티스학 및 기타 분야로 세분화됩니다. 면역학 분야는 2025년 시장 매출 점유율이 가장 높았는데, 이는 원발성 면역결핍증 및 자가면역 질환 치료에 널리 사용되고 있으며, 정맥주사 면역글로불린(IVIG)에 대한 전 세계 수요 증가에 힘입은 것입니다.
면역학 분야는 2025년부터 2032년까지 가장 빠른 CAGR을 기록할 것으로 예상되며, 이는 자가면역 질환의 유병률 증가, 인구 고령화, 면역글로불린 치료법의 임상 적용 확대에 힘입은 것입니다.
- 가공 기술로
처리 기술을 기준으로 시장은 이온 교환 크로마토그래피, 친화성 크로마토그래피, 동결침전, 한외여과, 정밀여과로 구분됩니다. 이온 교환 크로마토그래피 부문은 면역글로불린, 알부민, 응고 인자와 같은 혈장 단백질 정제에 있어 높은 효율, 확장성, 그리고 효과성을 바탕으로 2025년 시장 매출 점유율 1위를 차지했습니다.
친화성 크로마토그래피 부문은 2025년부터 2032년까지 가장 빠른 CAGR을 기록할 것으로 예상되며, 높은 특이성, 표적 단백질 분리 능력, 고급 생물학적 정제 분야에서의 채택 증가로 선호됩니다.
- 모드별
시장은 방식에 따라 현대식 혈장 분획법과 전통식 혈장 분획법으로 구분됩니다. 현대식 혈장 분획법은 첨단 처리 기술, 더 높은 제품 순도, 향상된 안전성 프로파일, 그리고 재조합 및 고수율 혈장 유래 치료법의 도입 증가를 주도하며 2025년 시장 매출 점유율 1위를 차지했습니다.
현대 분야는 정제 기술의 혁신, 더 안전한 생물학 제제에 대한 수요 증가, 차세대 플라즈마 처리 기술에 대한 투자 증가로 인해 2025년부터 2032년까지 가장 빠른 CAGR을 보일 것으로 예상됩니다.
- 최종 사용자별
최종 사용자 기준으로 시장은 병원 및 진료소, 연구소, 학술 기관 등으로 세분화됩니다. 병원 및 진료소 부문은 2025년에 가장 큰 시장 매출 점유율을 차지했는데, 이는 높은 환자 수, 전문 치료 접근성, 만성 질환 치료 증가, 그리고 첨단 혈장 유래 치료법 접근성 덕분입니다.
병원 및 진료소 부문도 2025년부터 2032년까지 가장 빠른 CAGR을 기록할 것으로 예상되며, 이는 의료 인프라 확장, 입원 환자 증가, 복잡한 질환에 대한 플라스마 치료법 의존도 증가에 힘입은 것입니다.
- 유통 채널별
유통 채널을 기준으로 시장은 직접 입찰, 제3자 유통업체, 그리고 기타 업체로 구분됩니다. 직접 입찰 부문은 정부 기관의 대량 구매, 비용 효율성, 안정적인 공급망, 그리고 혈장 유래 의약품에 대한 공공 부문 투자 증가에 힘입어 2025년 시장 매출 점유율이 가장 높았습니다.
직접 입찰 부문은 정부 의료 프로그램 확대, 중앙 조달 정책 강화, 비용 효율적인 대규모 혈장 치료 유통에 대한 수요 증가에 힘입어 2025년부터 2032년까지 가장 빠른 CAGR을 기록할 것으로 예상됩니다.
혈장 및 혈장 유래 의약품 시장 지역 분석
- 독일은 18.16%의 가장 큰 매출 점유율로 혈장 및 혈장 유래 의약품 시장을 지배하고 있으며, 첨단 의료 인프라, 희귀 및 만성 질환의 진단율 증가, 1인당 의료비 지출 증가로 인해 2025년에는 7.56%의 가장 빠른 CAGR로 성장할 것으로 예상됩니다.
- 국가의 강력한 규제 프레임워크, 견고한 상환 시스템, Grifols, CSL Behring, Takeda와 같은 주요 시장 참여자의 존재는 유럽이 혈장 수집 및 치료 유통 분야에서 선두를 차지하는 데 기여합니다.
- 주요 경제권에서는 생물약학 R&D에 막대한 투자를 하고 있으며, 혈장 수집 네트워크를 확대하고 면역학, 혈액학, 신경학 분야에서 혈장 유래 치료법에 대한 접근성을 개선하고 있습니다.
프랑스 혈장 및 혈장 유래 의약품 시장 통찰력
프랑스는 2025년부터 2032년까지 유럽 지역에서 강력한 성장을 보일 것으로 예상됩니다. 이는 탄탄한 의료 생태계, 희귀 및 만성 질환 환자 증가, 그리고 혈장 기증을 장려하는 정부의 적극적인 정책에 기인합니다. 프랑스는 수많은 혈장 수집 센터를 보유하고 있으며, PDMP(혈장분획제제) 승인도 가속화되어 치료 접근성을 높이고 시장 확대를 촉진합니다.
영국 혈장 및 혈장 유래 의약품 시장 통찰력
영국은 보편적 의료 시스템, 희귀 질환에 대한 인식 제고, 그리고 정부의 국내 혈장 수집 역량 확대 투자에 힘입어 2025년부터 2032년까지 이 지역에서 상당한 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다. 전략적 파트너십과 생물의약품 제조 분야의 발전은 PDMPs 분야에서의 입지를 강화하고 있습니다.
혈장 및 혈장 유래 의약품 시장 점유율
혈장 및 혈장 유래 의약품 산업은 주로 다음을 포함한 잘 확립된 회사들이 주도하고 있습니다.
- CSL(호주)
- 다케다제약 주식회사(일본)
- 그리폴스, SA(스페인)
- 옥타파마 AG(스위스)
- 케드리온(이탈리아)
- Bharat Serums(인도)
- Biotest AG(독일)
- 프레제니우스 카비 AG(독일)
- Intas Pharmaceuticals Ltd.(인도)
- 카마다제약(이스라엘)
- KM Biologics(일본)
- LFB(미국)
- Reliance Life Sciences(인도)
- SK플라즈마(한국)
- Synthaverse SA(폴란드)
- VIRCHOW BIOTECH(인도)
혈장 및 혈장 유래 의약품 시장의 최신 동향
- 2024년 11월, CSL Plasma는 콜로라도주 덴버 인근 6개 미국 헌혈 센터에 첨단 Rika 혈장 헌혈 시스템 도입을 확대했습니다. Terumo Blood & Cell Technologies와 공동 개발한 이 새로운 기기는 헌혈자의 편의성, 안전성, 효율성을 향상하는 동시에 채혈 시간을 약 30% 단축했습니다.
- 2022년 12월, CSL은 호주 빅토리아주에 브로드메도우즈 혈장 분획 시설을 준공했습니다. 이 시설은 남반구 최대 규모의 혈장 곡물 처리 시설입니다. 연간 920만 리터의 혈장 환산량을 처리할 수 있는 9억 달러 규모의 이 시설은 면역 결핍, 신경 질환, 그리고 이식이나 화상과 같은 중증 질환을 치료하는 혈장 기반 치료법에 대한 전 세계 수요를 충족합니다.
- 2024년 6월, 다케다는 용량 기준 세계 최고 수준인 로스앤젤레스 혈장 분획 시설의 3천만 달러 확장을 발표했습니다. 이번 시설 확충을 통해 연간 최대 200만 리터의 생산량이 증가할 것으로 예상되며, 면역결핍 및 출혈성 질환 치료에 사용되는 혈장 유래 치료제에 대한 전 세계 수요 증가에 대응할 수 있을 것으로 기대됩니다.
- 2023년, 다케다는 일본 오사카에 약 7억 6,500만 달러를 투자하여 새로운 혈장 유래 치료제 생산 공장을 건설했습니다. 이는 기존 나리타 공장의 생산 능력을 거의 5배로 늘리는 것입니다. 이 시설은 2030년까지 완전 가동될 예정이며, 일본과 글로벌 시장 모두에 서비스를 제공할 것입니다.
- 2025년 3월 Grifols는 Inpeco와 협력하여 고급 자동화 로봇(FlexLab X), 진단 및 시약을 통합하여 수혈에서 처리량이 높고 안전하고 추적 가능한 혈액 및 혈장 검사를 위한 "미래의 실험실"을 만들었습니다. 의학 실험실은 생물학적 샘플을 분석하여 질병을 진단, 모니터링 및 연구합니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE ANALYSIS
4.1.1 POLITICAL FACTORS
4.1.2 ECONOMIC FACTORS
4.1.3 SOCIAL FACTORS
4.1.4 TECHNOLOGICAL FACTORS
4.1.5 ENVIRONMENTAL FACTORS
4.1.6 LEGAL FACTORS
4.2 PORTER’S FIVE FORCES
4.2.1 THREAT OF NEW ENTRANTS
4.2.2 BARGAINING POWER OF SUPPLIERS
4.2.3 BARGAINING POWER OF BUYERS
4.2.4 THREAT OF SUBSTITUTES
4.2.5 INDUSTRY RIVALRY
4.3 SUPPLY CHAIN IMPACT ON THE EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET
4.3.1 OVERVIEW
4.3.2 RAW MATERIAL AVAILABILITY
4.3.3 MANUFACTURING CAPACITY
4.3.4 LOGISTICS AND LAST-MILE HURDLES
4.3.5 PRICING MODELS AND MARKET POSITIONING
4.4 INNOVATION STRATEGIES
4.4.1 KEY INNOVATION STRATEGIES
4.4.2 EMERGING DELIVERY TECHNIQUES
4.4.3 STRATEGIC IMPLICATIONS
4.4.4 CONCLUSION
4.5 RISK AND MITIGATION
4.6 VENDOR SELECTION DYNAMICS
4.6.1 PRODUCT QUALITY AND REGULATORY COMPLIANCE
4.6.2 SUPPLY CHAIN CAPABILITIES AND RELIABILITY
4.6.3 CLINICAL EFFICACY AND INNOVATION
4.6.4 COST COMPETITIVENESS AND REIMBURSEMENT COMPATIBILITY
4.6.5 LOCAL MARKET PRESENCE AND SUPPORT INFRASTRUCTURE
4.6.6 ETHICAL SOURCING, ESG COMPLIANCE, AND TRANSPARENCY
4.6.7 CONCLUSION
4.7 TARIFFS AND THEIR IMPACT ON MARKET
4.7.1 CURRENT TARIFF RATES IN TOP-5 COUNTRY MARKETS
4.7.2 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE
4.7.3 VENDOR SELECTION CRITERIA DYNAMICS
4.7.4 IMPACT ON SUPPLY CHAIN
4.7.5 IMPACT ON PRICES
4.7.6 REGULATORY INCLINATION
4.7.6.1 GCC TRADE ALIGNMENT & FTAS
4.7.6.2 SPECIAL ZONES AND RE-EXPORT MODELS
4.7.6.3 LOCAL SUBSIDY & POLICY RESPONSE
4.7.6.4 DOMESTIC COURSE OF CORRECTION
5 REGULATION COVERAGE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF RARE AND CHRONIC DISEASES
6.1.2 EXPANDING GERIATRIC POPULATION
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN PLASMA FRACTIONATION
6.1.4 GOVERNMENT AND INSTITUTIONAL SUPPORT
6.2 RESTRAINTS
6.2.1 HIGH COST AND COMPLEX MANUFACTURING PROCESS
6.2.2 LACK OF PLASMA SUPPLY AND DONOR
6.3 OPPORTUNITIES
6.3.1 ADVANCEMENTS IN PLASMA PROCESSING TECHNOLOGIES TO ENHANCE YIELD AND REDUCE COSTS
6.3.2 REIMBURSEMENT FRAMEWORKS AND INCREASED GOVERNMENTAL FOCUS ON RARE DISEASE TREATMENT
6.3.3 STRATEGIC ALLIANCES, MERGERS, AND ACQUISITIONS TO STRENGTHEN EUROPE MARKET PENETRATION
6.4 CHALLENGES
6.4.1 COMPETITIVE PRESSURE FROM RECOMBINANT AND ALTERNATIVE BIOLOGICAL THERAPIES
6.4.2 INFRASTRUCTURE LIMITATIONS IN COLD CHAIN LOGISTICS IMPACTING PRODUCT DISTRIBUTION
7 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT
7.1 OVERVIEW
7.2 IMMUNOGLOBULINS
7.3 COAGULATION FACTORS (FOR BLEEDING DISORDERS)
7.4 ALBUMIN (PLASMA VOLUME EXPANDER)
7.5 PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES)
7.6 MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS)
7.7 OTHER PLASMA DERIVED PROTEINS
8 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 IMMUNOLOGY
8.3 HEMATOLOGY
8.4 CRITICAL CARE
8.5 NEUROLOGY
8.6 PULMONOLOGY
8.7 HAEMATO-ONCOLOGY
8.8 RHEUMATOLOGY
8.9 OTHER APPLICATIONS
9 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 ION EXCHANGE CHROMATOGRAPHY
9.3 AFFINITY CHROMATOGRAPHY
9.4 CRYOPRECIPITATION
9.5 ULTRAFILTRATION
9.6 MICROFILTRATION
10 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE
10.1 OVERVIEW
10.2 MODERN
10.3 TRADITIONAL PLASMA FRACTIONATION
11 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS & CLINICS
11.3 RESEARCH LABS
11.4 ACADEMIC INSTITUTES
11.5 OTHERS
12 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDERS
12.3 THIRD PARTY DISTRIBUTORS
12.4 OTHERS
13 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 FRANCE
13.1.3 U.K
13.1.4 ITALY
13.1.5 SPAIN
13.1.6 RUSSIA
13.1.7 TURKEY
13.1.8 NETHERLANDS
13.1.9 SWITZERLAND
13.1.10 POLAND
13.1.11 DENMARK
13.1.12 SWEDEN
13.1.13 BELGIUM
13.1.14 IRELAND
13.1.15 NORWAY
13.1.16 FINLAND
13.1.17 REST OF EUROPE
14 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 CSL
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 GRIFOLS, S.A.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 OCTAPHARMA AG
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 KEDRION
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 ADMA BIOLOGICS, INC
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 AEGROS
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 BHARAT SERUMS
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 BIOTEST AG.
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 FRESENIUS KABI AG
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 GC BIOPHARMA CORPORATE
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 ICHOR
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 INTAS PHARMACEUTICALS LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 KAMADA PHARMACEUTICALS
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 KM BIOLOGICS
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 LFB
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENT
16.17 PLASMAGEN BIOSCIENCES PVT. LTD.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 PROLIANT HEALTH & BIOLOGICALS
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 PROMEA
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
16.2 RELIANCE LIFE SCIENCES
16.20.1 COMPANY SNAPSHOT
16.20.2 BUSINESS PORTFOLIO
16.20.3 RECENT DEVELOPMENT
16.21 SICHUAN YUANDA SHYUANG PHARMACEUTICAL CO., LTD.
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
16.22 SK PLASMA
16.22.1 COMPANY SNAPSHOT
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENT
16.23 SYNTHAVERSE S. A.
16.23.1 COMPANY SNAPSHOT
16.23.2 REVENUE ANALYSIS
16.23.3 PRODUCT PORTFOLIO
16.23.4 RECENT DEVELOPMENTS
16.24 TAIBANG BIO GROUP CO., LTD
16.24.1 COMPANY SNAPSHOT
16.24.2 PRODUCT PORTFOLIO
16.24.3 RECENT DEVELOPMENT
16.25 VIRCHOW BIOTECH
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
표 목록
TABLE 1 REGULATORY FRAMEWORK AND GUIDELINES
TABLE 2 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 3 EUROPE IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 4 EUROPE IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 5 EUROPE INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 6 EUROPE INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 7 EUROPE COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 8 EUROPE COAGULATION FACTORS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 9 EUROPE FACTOR IX IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 10 EUROPE RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 11 EUROPE FACTOR VIII IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 12 EUROPE RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 13 EUROPE FIBRINOGEN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 14 EUROPE PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 15 EUROPE VON WILLEBRAND FACTOR (VWF) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 16 EUROPE FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 17 EUROPE FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 18 IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 19 EUROPE ALBUMIN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 20 EUROPE PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES)IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 21 EUROPE PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 22 EUROPE ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 23 EUROPE C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 24 EUROPE MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS )IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 25 EUROPE MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 26 EUROPE OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 27 EUROPE OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 28 EUROPE ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)
TABLE 29 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2025-2032 (USD THOUSAND)
TABLE 30 EUROPE IMMUNOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 31 EUROPE HEMATOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 32 EUROPE CRITICAL CARE IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 33 EUROPE NEUROLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 34 EUROPE PULMONOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 35 EUROPE HEMATOLOGY -ONCOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 36 EUROPE RHEUMATOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 37 EUROPE OTHER APPLICATIONS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 38 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY, 2025-2032 (USD THOUSAND)
TABLE 39 EUROPE ION EXCHANGE CHROMATOGRAPHY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 40 EUROPE AFFINITY CHROMATOGRAPHY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 41 EUROPE CRYOPRECIPITATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 42 EUROPE ULTRAFILTRATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 43 EUROPE MICROFILTRATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 44 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2025-2032 (USD THOUSAND)
TABLE 45 EUROPE MODERN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 46 EUROPE TRADITIONAL PLASMA FRACTIONATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 47 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2025-2032 (USD THOUSAND)
TABLE 48 EUROPE HOSPITALS & CLINICS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 49 EUROPE RESEARCH LABS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 50 EUROPE ACADEMIC INSTITUTES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 51 EUROPE OTHERS BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 52 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
TABLE 53 EUROPE DIRECT TENDERS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 54 EUROPE THIRD PARTY DISTRIBUTORS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 55 EUROPE OTHERS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)
TABLE 56 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 57 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 58 EUROPE IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 59 EUROPE INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 EUROPE INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 EUROPE COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 EUROPE FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 EUROPE RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 EUROPE FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 EUROPE RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 EUROPE FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 EUROPE PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 EUROPE VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 EUROPE FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 EUROPE FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 EUROPE ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 72 EUROPE PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 EUROPE ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 EUROPE C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 EUROPE MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 EUROPE OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 EUROPE ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 79 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 80 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 81 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 82 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 83 GERMANY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 84 GERMANY IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 GERMANY INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 GERMANY INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 GERMANY COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 GERMANY FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 89 GERMANY RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 GERMANY FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 GERMANY RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 GERMANY FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 GERMANY PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 GERMANY VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 GERMANY FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 GERMANY FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 97 GERMANY ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 GERMANY PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 GERMANY ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 GERMANY C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 GERMANY MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 GERMANY OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 GERMANY ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 GERMANY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 105 GERMANY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 106 GERMANY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 107 GERMANY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 108 GERMANY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 109 FRANCE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 110 FRANCE IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 FRANCE INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 FRANCE INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 FRANCE COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 FRANCE FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 FRANCE RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 FRANCE FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 FRANCE RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 FRANCE FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 FRANCE PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 FRANCE VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 FRANCE FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 GERMANY FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 FRANCE FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 FRANCE ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 FRANCE PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 FRANCE ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 FRANCE C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 FRANCE MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 FRANCE OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 FRANCE ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 131 FRANCE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 132 FRANCE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 133 FRANCE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 134 FRANCE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 135 FRANCE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 136 U.K. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 137 U.K. IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 U.K. INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 U.K. INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 U.K. COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 U.K. FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 U.K. RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 U.K. FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 U.K. RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 U.K. FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 U.K. PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 U.K. VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 U.K. FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 U.K. FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 U.K. ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 U.K. PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 U.K. ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 U.K. C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 U.K. MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 U.K. OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 156 U.K. ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 U.K. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 158 U.K. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 159 U.K. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 160 U.K. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 161 U.K. BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 162 ITALY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 163 ITALY IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 ITALY INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 ITALY INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 ITALY COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 ITALY FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 ITALY RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 ITALY FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 ITALY RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 ITALY FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 172 ITALY PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 173 ITALY VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 174 ITALY FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 ITALY FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 ITALY ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 ITALY PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 ITALY ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 ITALY C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 180 ITALY MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 ITALY OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 ITALY ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 183 ITALY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 184 ITALY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 185 ITALY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 186 ITALY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 187 ITALY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 188 SPAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 189 SPAIN IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 SPAIN INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 SPAIN INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 SPAIN COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 SPAIN FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 SPAIN RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 SPAIN FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 SPAIN RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 SPAIN FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 SPAIN PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 SPAIN VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 SPAIN FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 SPAIN FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 SPAIN ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 SPAIN PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 SPAIN ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 SPAIN C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 SPAIN MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 SPAIN OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 SPAIN ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 SPAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 210 SPAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 211 SPAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 212 SPAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 213 SPAIN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 214 RUSSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 215 RUSSIA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 RUSSIA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 RUSSIA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 RUSSIA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 RUSSIA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 RUSSIA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 RUSSIA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 RUSSIA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 RUSSIA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 224 RUSSIA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 RUSSIA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 RUSSIA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 RUSSIA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 RUSSIA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 RUSSIA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 RUSSIA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 RUSSIA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 RUSSIA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 RUSSIA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 234 RUSSIA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 235 RUSSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 236 RUSSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 237 RUSSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 238 RUSSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 239 RUSSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 240 TURKEY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 241 TURKEY IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 242 TURKEY INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 TURKEY INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 244 TURKEY COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 245 TURKEY FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 TURKEY RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 TURKEY FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 248 TURKEY RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 249 TURKEY FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 250 TURKEY PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 TURKEY VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 252 TURKEY FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 TURKEY FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 TURKEY ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 TURKEY PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 TURKEY ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 TURKEY C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 TURKEY MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 TURKEY OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 TURKEY ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 TURKEY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 262 TURKEY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 263 TURKEY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 264 TURKEY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 265 TURKEY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 266 NETHERLANDS BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 267 NETHERLANDS IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 NETHERLANDS INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 NETHERLANDS INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 NETHERLANDS COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 271 NETHERLANDS FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 272 NETHERLANDS RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 NETHERLANDS FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 274 NETHERLANDS RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 NETHERLANDS FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 NETHERLANDS PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 NETHERLANDS VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 278 NETHERLANDS FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 NETHERLANDS FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 280 NETHERLANDS ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 281 NETHERLANDS PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 NETHERLANDS ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 NETHERLANDS C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 284 NETHERLANDS MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 NETHERLANDS OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 286 NETHERLANDS ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 NETHERLANDS BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 288 NETHERLANDS BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 289 NETHERLANDS BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 290 NETHERLANDS BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 291 NETHERLANDS BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 292 SWITZERLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 293 SWITZERLAND IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 SWITZERLAND INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 295 SWITZERLAND INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 SWITZERLAND COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 297 SWITZERLAND FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 SWITZERLAND RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 SWITZERLAND FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 SWITZERLAND RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 SWITZERLAND FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 SWITZERLAND PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 303 SWITZERLAND VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 SWITZERLAND FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 SWITZERLAND FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 SWITZERLAND ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 SWITZERLAND PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 308 SWITZERLAND ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 309 SWITZERLAND C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 310 SWITZERLAND MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 SWITZERLAND OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 312 SWITZERLAND ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 313 SWITZERLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 314 SWITZERLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 315 SWITZERLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 316 SWITZERLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 317 SWITZERLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 318 POLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 319 POLAND IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 POLAND INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 321 POLAND INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 322 POLAND COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 323 POLAND FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 POLAND RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 POLAND FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 POLAND RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 POLAND FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 328 POLAND PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 329 POLAND VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 330 POLAND FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 POLAND FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 POLAND ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 333 POLAND PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 334 POLAND ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 335 POLAND C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 336 POLAND MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 337 POLAND OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 338 POLAND ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 339 POLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 340 POLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 341 POLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 342 POLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 343 POLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 344 DENMARK BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 345 DENMARK IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 DENMARK INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 347 DENMARK INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 348 DENMARK COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 349 DENMARK FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 DENMARK RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 DENMARK FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 DENMARK RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 353 DENMARK FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 DENMARK PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 DENMARK VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 DENMARK FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 DENMARK FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 358 DENMARK ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 359 DENMARK PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 360 DENMARK ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 361 DENMARK C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 362 DENMARK MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 363 DENMARK OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 364 DENMARK ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 365 DENMARK BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 366 DENMARK BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 367 DENMARK BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 368 DENMARK BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 369 DENMARK BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 370 SWEDEN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 371 SWEDEN IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 SWEDEN INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 373 SWEDEN INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 374 SWEDEN COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 375 SWEDEN FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 376 SWEDEN RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 377 SWEDEN FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 378 SWEDEN RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 SWEDEN FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 380 SWEDEN PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 381 SWEDEN VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 382 SWEDEN FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 383 SWEDEN FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 384 SWEDEN ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 385 SWEDEN PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 386 SWEDEN ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 SWEDEN C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 388 SWEDEN MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 389 SWEDEN OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 SWEDEN ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 391 SWEDEN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 392 SWEDEN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 393 SWEDEN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 394 SWEDEN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 395 SWEDEN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 396 BELGIUM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 397 BELGIUM IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 398 BELGIUM INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 399 BELGIUM INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 400 BELGIUM COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 BELGIUM FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 402 BELGIUM RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 403 BELGIUM FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 404 BELGIUM RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 405 BELGIUM FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 406 BELGIUM PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 407 BELGIUM VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 BELGIUM FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 BELGIUM FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 410 BELGIUM ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 411 BELGIUM PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 BELGIUM ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 413 BELGIUM C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 414 BELGIUM MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 BELGIUM OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 BELGIUM ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 BELGIUM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 418 BELGIUM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 419 BELGIUM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 420 BELGIUM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 421 BELGIUM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 422 IRELAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 423 IRELAND IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 424 IRELAND INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 IRELAND INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 IRELAND COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 427 IRELAND FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 428 IRELAND RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 429 IRELAND FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 430 IRELAND RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 431 IRELAND FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 432 IRELAND PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 433 IRELAND VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 434 IRELAND FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 435 IRELAND FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 436 IRELAND ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 IRELAND PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 438 IRELAND ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 439 IRELAND C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 IRELAND MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 441 IRELAND OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 442 IRELAND ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 IRELAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 444 IRELAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 445 IRELAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 446 IRELAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 447 IRELAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 448 NORWAY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 449 NORWAY IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 NORWAY INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 NORWAY INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 NORWAY COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 453 NORWAY FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 454 NORWAY RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 455 NORWAY FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 NORWAY RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 NORWAY FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 458 NORWAY PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 NORWAY VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 460 NORWAY FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 461 NORWAY FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 462 NORWAY ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 463 NORWAY PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 464 NORWAY ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 465 NORWAY C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 466 NORWAY MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 467 NORWAY OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 468 NORWAY ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 469 NORWAY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 470 NORWAY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 471 NORWAY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 472 NORWAY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 473 NORWAY BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 474 FINLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 475 FINLAND IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 476 FINLAND INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 477 FINLAND INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 478 FINLAND COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 479 FINLAND FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 480 FINLAND RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 481 FINLAND FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 FINLAND RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 483 FINLAND FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 484 FINLAND PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 485 FINLAND VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 486 FINLAND FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 FINLAND FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 488 FINLAND ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 489 FINLAND PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 490 FINLAND ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 491 FINLAND C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 492 FINLAND MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 493 FINLAND OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 494 FINLAND ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 495 FINLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 496 FINLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 497 FINLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)
TABLE 498 FINLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 499 FINLAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 500 REST OF EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
그림 목록
FIGURE 1 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SEGMENTATION
FIGURE 2 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SEGMENTATION
FIGURE 12 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT (2024)
FIGURE 13 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 RISING PREVALENCE OF RARE AND CHRONIC DISEASES IS EXPECTED TO DRIVE THE EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 16 IMMUNOGLOBULINS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 17 PORTER’S FIVE FORCES
FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES FOR THE EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET
FIGURE 19 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, 2024
FIGURE 20 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, 2025-2032 (USD THOUSAND)
FIGURE 21 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, CAGR (2025-2032) (2025-2032)
FIGURE 22 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 23 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, 2024
FIGURE 24 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)
FIGURE 25 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, CAGR (2025-2032) (2025-2032)
FIGURE 26 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, 2024
FIGURE 28 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, 2025-2032 (USD THOUSAND)
FIGURE 29 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, CAGR (2025-2032) (2025-2032)
FIGURE 30 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 31 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, 2024
FIGURE 32 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, 2025-2032 (USD THOUSAND)
FIGURE 33 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, CAGR (2025-2032) (2025-2032)
FIGURE 34 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, LIFELINE CURVE
FIGURE 35 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, 2024
FIGURE 36 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 37 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, CAGR (2025-2032) (2025-2032)
FIGURE 38 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 40 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 41 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032) (2025-2032)
FIGURE 42 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SNAPSHOT (2024)
FIGURE 44 EUROPE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: COMPANY SHARE 2024 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
